Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Advanced prostate cancer overview: Expert discussion

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.01.16
Views: 3997

Dr Heather Payne, Prof Romano Danesi, Prof Luis da Costa, Prof Peter Mulders

Dr Payne (University College Hospital, London, UK) chairs a discussion for ecancertv with Prof Danesi (University of Pisa, Pisa, Italy), Prof da Costa (Hospital de Santa Maria, Lisbon, Portugal) and Prof Mulders (Radboud University, Nijmegen, The Netherlands) about the main points coming from the 2016 Prostate Debate in Copenhagen.

In particular, they discuss the role of docetaxel chemotherapy in hormone-sensitive prostate cancer and the role of drug combinations such as zoledronic acid and celecoxib.

They discuss the impact of the STAMPEDE trial, along with discussion of androgen deprivation therapy, COX inhibitors and side effects.

They also consider less invasive diagnosis and monitoring methods which harness blood-based biomarkers.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation